These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

379 related items for PubMed ID: 8261403

  • 1. Pharmacokinetics of recombinant human interleukin 3 administered subcutaneously and by continuous intravenous infusion in patients after chemotherapy for ovarian cancer.
    Biesma B, Pokorny R, Kovarik JM, Duffy FA, Willemse PH, Mulder NH, de Vries EG.
    Cancer Res; 1993 Dec 15; 53(24):5915-9. PubMed ID: 8261403
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of subcutaneous interleukin 3 in patients with refractory malignancy: hematological, immunological, and pharmacodynamic findings.
    Bukowski RM, Olencki T, Gunn H, McLain D, Budd GT, Sandstrom K, Tuason L, Redovan C, Rayman P, Tubbs R, Resta D, Elson P, Finke J.
    Clin Cancer Res; 1996 Feb 15; 2(2):347-57. PubMed ID: 9816178
    [Abstract] [Full Text] [Related]

  • 3. Recombinant human interleukin-3 to dose-intensify carboplatin and cyclophosphamide chemotherapy in epithelial ovarian cancer: a phase I trial.
    Veldhuis GJ, Willemse PH, van Gameren MM, Aalders JG, Mulder NH, Mull B, Biesma B, de Vries EG.
    J Clin Oncol; 1995 Mar 15; 13(3):733-40. PubMed ID: 7884433
    [Abstract] [Full Text] [Related]

  • 4. Phase I study and pharmacological analysis of cis-diammine(glycolato)platinum (254-S; NSC 375101D) administered by 5-day continuous intravenous infusion.
    Sasaki Y, Amano T, Morita M, Shinkai T, Eguchi K, Tamura T, Ohe Y, Kojima A, Saijo N.
    Cancer Res; 1991 Mar 01; 51(5):1472-7. PubMed ID: 1997185
    [Abstract] [Full Text] [Related]

  • 5. Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.
    Lazarus HM, Winton EF, Williams SF, Grinblatt D, Campion M, Cooper BW, Gunn H, Manfreda S, Isaacs RE.
    Bone Marrow Transplant; 1995 Jun 01; 15(6):935-42. PubMed ID: 7581094
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic and pharmacodynamic studies of subcutaneously administered recombinant human interleukin-3 following chemotherapy for non-Hodgkin's lymphoma.
    Hovgaard DJ, Mortensen BT, Nissen NI.
    Br J Haematol; 1995 Oct 01; 91(2):367-73. PubMed ID: 8547077
    [Abstract] [Full Text] [Related]

  • 7. Phase I trial of recombinant interleukin 3 before and after carboplatin/etoposide chemotherapy in patients with solid tumors: a southwest oncology group study.
    Rinehart J, Margolin KA, Triozzi P, Hersh E, Campion M, Resta D, Levitt D.
    Clin Cancer Res; 1995 Oct 01; 1(10):1139-44. PubMed ID: 9815905
    [Abstract] [Full Text] [Related]

  • 8. Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies.
    Atkins MB, Robertson MJ, Gordon M, Lotze MT, DeCoste M, DuBois JS, Ritz J, Sandler AB, Edington HD, Garzone PD, Mier JW, Canning CM, Battiato L, Tahara H, Sherman ML.
    Clin Cancer Res; 1997 Mar 01; 3(3):409-17. PubMed ID: 9815699
    [Abstract] [Full Text] [Related]

  • 9. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
    Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kuritani J.
    Clin Cancer Res; 1998 Sep 01; 4(9):2085-8. PubMed ID: 9748123
    [Abstract] [Full Text] [Related]

  • 10. [Efficiency, safety and tolerability of recombinant human interleukin-3 (rhIL-3) as supportive therapy accompanying dose-intensive carboplatin containing chemotherapy in ovarian cancer with special regard to thrombocytopenia].
    Meden H, Fock M, Krauss T, Kuhn W.
    Zentralbl Gynakol; 1999 Sep 01; 121(8):375-83. PubMed ID: 10486880
    [Abstract] [Full Text] [Related]

  • 11. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 12. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
    Chen SA, Sawchuk RJ, Brundage RC, Horvath C, Mendenhall HV, Gunther RA, Braeckman RA.
    J Pharmacol Exp Ther; 2000 Apr 01; 293(1):248-59. PubMed ID: 10734176
    [Abstract] [Full Text] [Related]

  • 13. Etoposide phosphate infusion with therapeutic drug monitoring in combination with carboplatin dosed by area under the curve: a cancer research campaign phase I/II committee study.
    Porter D, Boddy A, Thomas H, Lind M, Newell D, Calvert AH, Robson L, Brampton M, Abrahamsen D, Winograd B.
    Semin Oncol; 1996 Dec 01; 23(6 Suppl 13):34-44. PubMed ID: 8996574
    [Abstract] [Full Text] [Related]

  • 14. cis-Amminedichloro(2-methylpyridine) platinum(II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology, and pharmacokinetics in mice.
    Raynaud FI, Boxall FE, Goddard PM, Valenti M, Jones M, Murrer BA, Abrams M, Kelland LR.
    Clin Cancer Res; 1997 Nov 01; 3(11):2063-74. PubMed ID: 9815598
    [Abstract] [Full Text] [Related]

  • 15. High-dose idarubicin in combination with Ara-C in patients with relapsed or refractory acute lymphoblastic leukemia: a pharmacokinetic and clinical study.
    Tedeschi A, Montillo M, Strocchi E, Cafro AM, Tresoldi E, Intropido L, Nichelatti M, Marbello L, Baratè C, Camaggi CM, Morra E.
    Cancer Chemother Pharmacol; 2007 May 01; 59(6):771-9. PubMed ID: 17256136
    [Abstract] [Full Text] [Related]

  • 16. Phase I pharmacokinetic study of cyclosporin A combined with doxorubicin.
    Erlichman C, Moore M, Thiessen JJ, Kerr IG, Walker S, Goodman P, Bjarnason G, DeAngelis C, Bunting P.
    Cancer Res; 1993 Oct 15; 53(20):4837-42. PubMed ID: 8402670
    [Abstract] [Full Text] [Related]

  • 17. Intraperitoneal carboplatin infusion may be a pharmacologically more reasonable route than intravenous administration as a systemic chemotherapy. A comparative pharmacokinetic analysis of platinum using a new mathematical model after intraperitoneal vs. intravenous infusion of carboplatin--a Sankai Gynecology Study Group (SGSG) study.
    Miyagi Y, Fujiwara K, Kigawa J, Itamochi H, Nagao S, Aotani E, Terakawa N, Kohno I, Sankai Gynecology Study Group (SGSG).
    Gynecol Oncol; 2005 Dec 15; 99(3):591-6. PubMed ID: 16095677
    [Abstract] [Full Text] [Related]

  • 18. A phase I and pharmacokinetic study of melphalan using a 24-hour continuous infusion in patients with advanced malignancies.
    Pinguet F, Culine S, Bressolle F, Astre C, Serre MP, Chevillard C, Fabbro M.
    Clin Cancer Res; 2000 Jan 15; 6(1):57-63. PubMed ID: 10656432
    [Abstract] [Full Text] [Related]

  • 19. Carboplatin and short-infusion paclitaxel in high-risk and advanced-stage ovarian carcinoma.
    Coleman RL, Bagnell KG, Townley PM.
    Cancer J Sci Am; 1997 Jan 15; 3(4):246-53. PubMed ID: 9263631
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of treprostinil sodium administered by 28-day chronic continuous subcutaneous infusion.
    Wade M, Baker FJ, Roscigno R, DellaMaestra W, Arneson CP, Hunt TL, Lai AA.
    J Clin Pharmacol; 2004 May 15; 44(5):503-9. PubMed ID: 15102871
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.